company background image
OCC

Orthocell ASX:OCC Stock Report

Last Price

AU$0.47

Market Cap

AU$93.7m

7D

-1.0%

1Y

-6.9%

Updated

27 Nov, 2022

Data

Company Financials
OCC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

OCC Stock Overview

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia.

Orthocell Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Orthocell
Historical stock prices
Current Share PriceAU$0.47
52 Week HighAU$0.59
52 Week LowAU$0.30
Beta0.29
1 Month Change17.28%
3 Month Change26.67%
1 Year Change-6.86%
3 Year Change-15.93%
5 Year Change18.75%
Change since IPO31.94%

Recent News & Updates

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Nov 16
We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Jul 29
We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Recent updates

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Nov 16
We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Jul 29
We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Mar 23
Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

Dec 08
We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31
Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Feb 15
Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Dec 24
How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Shareholder Returns

OCCAU BiotechsAU Market
7D-1.0%1.7%1.2%
1Y-6.9%-6.8%-2.9%

Return vs Industry: OCC matched the Australian Biotechs industry which returned -6.8% over the past year.

Return vs Market: OCC underperformed the Australian Market which returned -2.9% over the past year.

Price Volatility

Is OCC's price volatile compared to industry and market?
OCC volatility
OCC Average Weekly Movement6.5%
Biotechs Industry Average Movement8.9%
Market Average Movement9.0%
10% most volatile stocks in AU Market16.1%
10% least volatile stocks in AU Market4.2%

Stable Share Price: OCC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: OCC's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aPaul Andersonhttps://orthocell.com

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair.

Orthocell Limited Fundamentals Summary

How do Orthocell's earnings and revenue compare to its market cap?
OCC fundamental statistics
Market CapAU$93.67m
Earnings (TTM)-AU$9.11m
Revenue (TTM)AU$1.53m

61.2x

P/S Ratio

-10.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OCC income statement (TTM)
RevenueAU$1.53m
Cost of RevenueAU$702.61k
Gross ProfitAU$829.11k
Other ExpensesAU$9.94m
Earnings-AU$9.11m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.046
Gross Margin54.13%
Net Profit Margin-594.53%
Debt/Equity Ratio0%

How did OCC perform over the long term?

See historical performance and comparison